Esperion Therapeutics, Inc. (NASDAQ:ESPR) headquartered in Ann Arbor, will host a conference call for the investment community to discuss the 2Q20 financial results on 10th August 2020 at 4:30 PM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.esperion.com
Earnings Expectation
Esperion Therapeutics, Inc. is reporting second quarter financial results on Monday 10th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ESPR is expected to report 2Q20 income of $ 1.71 per share from revenue of $ 147.97 million. For the full year, analysts anticipate top line of $ 244.75 million, while looking forward to loss of $ 5.1 per share bottom line.
Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination tablet, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH.
